Interferon-alpha-induced thyroid dysfunction in patients with chronic active hepatitis C: a transient, reversible and...

Area of Science:

• Endocrinology
• Hepatology
• Immunology

Background:

• Chronic active hepatitis C is often treated with interferon-alpha (IFNalpha).
• IFNalpha therapy is known to have potential side effects, including endocrine abnormalities.
• Thyroid dysfunction is a recognized, though not fully understood, complication of IFNalpha treatment.

Purpose of the Study:

• To investigate the incidence and prognosis of thyroid dysfunction in patients undergoing IFNalpha therapy for chronic active hepatitis C.
• To determine if IFNalpha-induced thyroid dysfunction requires treatment discontinuation.
• To assess the reversibility and self-limiting nature of thyroid abnormalities during IFNalpha therapy.

Main Methods:

• A cohort of 100 patients with biopsy-proven chronic active hepatitis C receiving IFNalpha therapy was studied.
• Thyroid function was monitored by measuring thyroid stimulating hormone (TSH) levels during and after IFNalpha treatment.
• A control group of 14 patients without IFNalpha therapy was included for comparison.

Main Results:

• Thyroid dysfunction, characterized by abnormal TSH levels, transient thyrotoxicosis, or transient hypothyroidism, occurred in 33.7% of patients on IFNalpha therapy.
• Thyroid function normalized spontaneously in all affected patients during the follow-up period without thyroid hormone supplementation.
• Thyroid abnormalities were significantly more frequent in the IFNalpha-treated group compared to the control group (7.1%).

Conclusions:

• Interferon-alpha therapy can induce transient and reversible thyroid dysfunction in patients with chronic active hepatitis C.
• The findings suggest IFNalpha may unmask or exacerbate pre-existing autoimmune thyroid conditions.
• Discontinuation of IFNalpha therapy is generally not necessary for managing IFNalpha-induced thyroid dysfunction.